404867-96-5

Upstream product

• 58479-61-1 tert-butylchlorodiphenylsilane 
• 404868-09-3 3,17-dihydroxy-heptadecanoic acid tert-butyl ester 
• 404867-95-4 17-hydroxy-3-oxo-heptadecanoic acid tert-butyl ester 
• 540-88-5 acetic acid tert-butyl ester 
• 106-02-5 pentadecanolide 

Downstream Products

• 404867-97-6 (3R)-tert-butyl [17-tert-butyldiphenylsilyloxy-3-(2,3,4-tri-O-benzyl-6-O-acetyl-β-D-glucopyranosyl)oxy]heptadecanoate 
• 704910-56-5 (3R)-tert-butyl [17-tert-butyldiphenylsilyloxy-3-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)oxy]heptadecanoate 
• 628316-39-2 (3R,17R,23R)-3-((2R,3R,4S,5R,6R)-6-Acetoxymethyl-3,4,5-tris-benzyloxy-tetrahydro-pyran-2-yloxy)-23-benzyloxy-17-hydroxy-tetracosanoic acid tert-butyl ester 
• 628316-18-7 (R)-3-((2R,3R,4S,5R,6R)-6-Acetoxymethyl-3,4,5-tris-benzyloxy-tetrahydro-pyran-2-yloxy)-17-(1-phenyl-1H-tetrazol-5-ylsulfanyl)-heptadecanoic acid tert-butyl ester 
• 404867-98-7 (R)-17-(tert-Butyl-diphenyl-silanyloxy)-3-((2R,3R,4S,5R,6R)-3,4,5-tris-benzyloxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-heptadecanoic acid 
• 704910-67-8 (3R,17S,23R)-23-Benzyloxy-17-hydroxy-3-((2R,3R,4S,5R,6R)-3,4,5-tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-yloxy)-tetracosanoic acid tert-butyl ester 
• 704910-65-6 (3R)-tert-butyl [3-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)oxy]heptadecanoate 
• 704910-66-7 (R)-17-Oxo-3-((2R,3R,4S,5R,6R)-3,4,5-tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-yloxy)-heptadecanoic acid tert-butyl ester 
• 628316-38-1 (3R,17S,23R)-3-((2R,3R,4S,5R,6R)-6-Acetoxymethyl-3,4,5-tris-benzyloxy-tetrahydro-pyran-2-yloxy)-23-benzyloxy-17-hydroxy-tetracosanoic acid tert-butyl ester 
• 628316-35-8 (3R)-tert-butyl-[3-(6-O-acetyl-2,3,4-tri-O-benzyl-β-D-glucopyranosyl)oxy]heptadecanoate 
• 628316-36-9 (R)-3-((2R,3R,4S,5R,6R)-6-Acetoxymethyl-3,4,5-tris-benzyloxy-tetrahydro-pyran-2-yloxy)-17-oxo-heptadecanoic acid tert-butyl ester 

Relevant academic research and scientific papers

Structure Assignment, Total Synthesis, and Antiviral Evaluation of Cycloviracin B1

The first total synthesis of the antivirally active glycolipid cycloviracin B1 (1) is described. The approach is based on a two-directional synthesis strategy which constructs the C 2-symmetrical macrodiolide core of the target by an

A concise synthesis of the fully functional lactide core of cycloviracin B with implications for the structural assignment of related glycolipids

The absolute stereochemistry at the site of attachment of the fatty acid residues to the lactide core of the glycolipids cycloviracin B1 (1) and glucolipsin A (13) has been elucidated as (3R,3-R) by comparison of their 13C NMR data w